Company Analysis
Sign in

Autolus Therapeutics plc (AUTL)

Nasdaq: AUTL · Biological Products, (No Diagnostic Substances) · London, GB · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.3
◀ Past 3.1● Present 5.3▶ Future 4.1
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Autolus Therapeutics plc

Nine metrics read from its own filings, by tense
Headline grade
4.3/10
◀ Past3.130% of the headline
● Present5.340% of the headline
▶ Future4.130% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 4 read as filed from the record and 5 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.1/1030% of the headline grade · 1 of 3 filed, 2 estimated

Surviving crises

as filed
0.6/10

Has it survived what it has been through?

3 warning events since 2018; the latest 2026-04-16.

weight 33% of this tense · 6th percentile among 159 sector filers · read for itself

From the record

Autolus Therapeutics plc's filings since 2018 show 3 warning events of 3 kinds: a warning not to rely on past financial statements (8-K item 4.02, the latest 2024-03-21); an auditor change (8-K item 4.01, the latest 2026-04-16); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-05-13) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

SI estimate
4.9/10

What has it actually done, year after year?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 45% of this tense · 50th percentile among 103 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
Fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 103 members with one.
What the record cannot read
Fewer than three filed years of revenue on file.
How it was reasoned
family median, 103 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Autolus Therapeutics plc's track record is put at 4.9 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 103 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Shareholder treatment

SI estimate
3.3/10

How has it treated the people who own it?

SI estimate 3.3/10, confidence 35 of 100 (one part).

weight 22% of this tense · 33rd percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 33% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Autolus Therapeutics plc's shareholder treatment is put at 3.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 33% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.3/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
3.2/10

Is it financially healthy right now?

ROE -161%: lost 161¢ per shareholder dollar. Leverage 70%: owes 70¢ per asset dollar.

weight 45% of this tense · 32nd percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Autolus Therapeutics plc lost about 161 cents for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 4 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 70 cents per dollar of assets, and net share issuance: its share count grew 4.3% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 31% of its family
  • return on equitybottom 17% of its family
  • gross profit against assetsbottom 5% of its family
  • the share count against the year beforetop 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
7.0/10

How strong is its position in its industry?

top 30% of 102 in its family; net margin -381.4%.

weight 33% of this tense · 70th percentile among 102 sector filers · read for its customers

From the record

Autolus Therapeutics plc's standing among 102 graded names in its industry family: revenue of $75 million in fiscal 2025 ranks in the top 33% by size; a net margin of -381.4% ranks in the bottom 46%; revenue growth of 646% a year over the last 1 filed years ranks in the top 3% (its annual reports).

What it rests on

  • revenue against the family$75.4Mtop 33% of its family
  • net margin-381.4%bottom 46% of its family
  • three-year revenue growth646.0%top 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
7.0/10

What are the people in charge doing?

SI estimate 7.0/10, confidence 35 of 100 (one part).

weight 22% of this tense · 70th percentile among 137 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 30% of 137 in its family; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read
The record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 137 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Autolus Therapeutics plc's leadership is put at 7.0 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 30% of 137 in its family; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.1/1030% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

as filed
3.0/10

How much room does it have to grow?

bottom 30% of 92 in its family for room to expand.

weight 45% of this tense · 30th percentile among 92 sector filers · read for itself

From the record

Autolus Therapeutics plc's room to grow, from the newest filed statements (fiscal 2025): cash of $104 million against no long-term debt tagged leaves 17.7% of its assets as net cash, bottom 31% of its family; cash from operations less capital spending is -401.4% of revenue (bottom 38%); a gross margin of -27.8% (bottom 5%); research spending of 156.1% of revenue (bottom 48%) (its annual report).

What it rests on

  • cash less debt against assets17.7%bottom 31% of its family
  • cash from operations less capital spending against revenue-401.4%bottom 38% of its family
  • gross margin-27.8%bottom 5% of its family
  • research spending against revenue156.1%bottom 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

SI estimate
4.9/10

What could actually drive growth from here?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 101 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 101 members with one.
What the record cannot read
The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned
family median, 101 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Autolus Therapeutics plc's growth drivers is put at 4.9 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 101 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Expectations vs reality

SI estimate
5.1/10

Did its newest year beat what its own record pointed to?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 73 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 73 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Autolus Therapeutics plc's expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton AUTL · research, not advice